Nature Communications (Apr 2025)

Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer

  • J. Saris,
  • A. Y. F. Li Yim,
  • S. Bootsma,
  • K. J. Lenos,
  • R. Franco Fernandez,
  • H. N. Khan,
  • J. Verhoeff,
  • D. Poel,
  • N. M. Mrzlikar,
  • L. Xiong,
  • M. P. Schijven,
  • N. C. T. van Grieken,
  • O. Kranenburg,
  • M. E. Wildenberg,
  • A. Logiantara,
  • C. Jongerius,
  • J. J. Garcia Vallejo,
  • S. S. Gisbertz,
  • S. Derks,
  • J. B. Tuynman,
  • G. R. A. M. D’Haens,
  • L. Vermeulen,
  • J. Grootjans

DOI
https://doi.org/10.1038/s41467-025-58999-6
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Patients with peritoneal metastasized colorectal cancer (PM-CRC) have a dismal prognosis. We hypothesized that an immunosuppressive environment in the peritoneal cavity underlies poor prognosis. We define the composition of the human peritoneal immune system (PerIS) using single-cell technologies in 18 patients with- and without PM-CRC, as well as in matched peritoneal metastases (n = 8). Here we show that the PerIS contains abundant immunosuppressive C1Q + VSIG4 + and SPP1 + VSIG4 + peritoneal-resident macrophages (PRMs), as well as monocyte-like cavity macrophages (mono-CMs), which share features with tumor-associated macrophages, even in homeostasis. In PM-CRC, expression of immunosuppressive cytokines IL10 and VEGF increases, while simultaneously expression of antigen-presenting molecules decreases in PRMs. These intratumoral suppressive PRMs originate from the PerIS, and intraperitoneal depletion of PRMs in vivo using anti-CSF1R combined with anti-PD1 significantly reduces tumor burden and improves survival. Thus, PRMs define a metastatic site-specific immunosuppressive niche, and targeting PRMs is a promising treatment strategy for PM-CRC.